Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With Anlotinib and a Tubulin Inhibitor for HER2-Negative Breast Cancer With Brain Metastases
NCT07396454Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Feb 2026; status: recruiting.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07396454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396454.